|
|
|
|
|
|
|
| Adenocarcinoma | ||
| Etiology • Least closely associated with cigarette smoking of all lung cancers • Radiation, air pollution and genetic predisposition may also play a role | ||
| Pathogenesis • BPDE (catabolite of benzo[a]pyrene in cigarette smoke) binds p53 mutational hot spots in lung carcinoma • p53 mutation affects cell replication and centromere replication, | ||
| Epidemiology • Accounts for 25-40% of all lung cancers. | ||
| General Gross Description • Often peripheral location • May involve the pleura causing puckering and scarring. • May be associated with pleural effusion • Cut surfaces often glisten and are yellow if abundant mucin secretion within the tumor • May be unassociated with large bronchus •Examples: | ||
| General Microscopic Description • Usual bronchial adenocarcinoma is gland forming • Mucus secretion may require special stains such as mucicarmine or PAS • Cells show large nuclei with prominent nucleoli • Variants include bronchoalveolar carcinoma which spreads along preexisting alveolar septae •Examples: | ||
| Clinical Correlation • Peripheral location associated with pleuritic chest pain and effusion. • Weight loss and dyspnea • Staging dependent on extent of disease ranging from I (confined to the lung with >2 cm distance from hilum and pleura) to IV (metastatic disease) • Metastases to lymph nodes, brain, liver, and adrenals • Surgical treatment is preferred; many patients have insufficient pulmonary reserve for treatment • Overall five year survival 10% | ||
| References • Cotran RS, Kumar V, Robbins SL: Robbins Pathologic Basis of Disease. 5th edition. Philadelphia, W.B. Saunders, 1994, pp. 720-25. Please be patient during transfer. Medline will open in a new window. To return, close the Medline Window Adenocarcinoma
| Synopsis by: Melinda Sanders M.D. (T28000M81403)[126]
| |
|
|
|
|
|
|